We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

Johnson & Johnson (NYSE:JNJ), a global healthcare leader, finds itself at a pivotal juncture as it navigates a landscape of ...

The deal would help accelerate growth in J&J's drugs business after the company spun off its consumer health unit in 2023.

Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest ...

Johnson & Johnson has struck a $14.6bn deal to buy neuroscience drugmaker Intra-Cellular Therapies, the US pharmaceutical company said, marking the biggest biotech buyout in more than a year.

Johnson & Johnson (J&J) is in talks to acquire Intra-Cellular Therapies Inc., a biopharmaceutical company focused on treatments for central nervous system disorders, people familiar with the matter ...

Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its ...

Johnson & Johnson (J&J) is in discussions to acquire Intra-Cellular Therapies in the biggest biotech transaction in more than a year.

J&J will buy all of Intra-Cellular's shares for $132 apiece, representing a 39% premium to their Friday closing price. Shares ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Johnson & Johnson is working on a bid for $10bn neuroscience drugmaker Intra-Cellular Therapies, in what would be the biggest ...

JOHNSON & Johnson (J&J) is in talks to acquire Intra-Cellular Therapies, a biopharmaceutical company focused on treatments ...